Summary and future research directions
In this review, we summarized the molecular mechanisms and clinical
experience in support of CBD as a potential therapeutic compound for
various diseases. Among them, CBD has been approved for the treatment of
seizures associated with Lennox-Gastaut and Dravet syndromes, as well as
tuberous sclerosis complex in the USA and EU. Further clinical and
mechanistic studies are necessary to fully explore the therapeutic
potential of CBD in various diseases. Although CBD exhibited promising
therapeutic benefits for some diseases in initial clinical trials, a
large percentage of clinical data comes from case studies or open-label
trials, which must be interpreted cautiously due to the absence of
placebo control, leading to possible biased effects associated with CBD
treatment. Therefore, more well-designed, randomized,
placebo-controlled, double-blind clinical trials with diverse
populations are needed to evaluate and support the therapeutic efficacy
and utility of CBD for multiple disease states.